Montpellier, September 7th 2023 – French medical robotics company Quantum Surgical has obtained CE mark approval for the expanded use of its robotic platform, Epione®, in the treatment of lung tumors. With over 2 million new cases worldwide in 2020, including approximately 500,000 in Europe, lung cancer is the leading cause of cancer-related mortality1. This new feature will be presented with related clinical study results at the CIRSE 2023 conference in Copenhagen from September 9th to 13th by Dr. Bonnet, interventional radiologist at Gustave Roussy.
Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.
Epione® can be used to treat abdominal tumors (including the liver, kidneys, and pancreas) and over 200 patients have already been treated in France and the United States.
The CE mark approval for lung tumors will expand this innovative, targeted, and minimally invasive treatment to new patients in Europe.
It is based on a clinical study conducted at Gustave Roussy, the leading cancer center in Europe (third worldwide), the results of which will be presented during the international scientific conference organized by CIRSE (Cardiovascular and Interventional Radiological Society of Europe).
“With Epione®, our goal is to provide patients with an effective, better targeted and minimally invasive treatment. While over 2 million new cases of lung cancer diagnosed each year worldwide, we are delighted that our technology can now be accessible to new patients in Europe” said Bertin Nahum, President and Co-founder of Quantum Surgical.
“Patients were treated at Gustave Roussy with thermal destruction of lung metastases as part of a clinical study investigating the feasibility and safety of robotic guidance. In this ongoing study, the Epione® robot has consistently enabled technical success and has proven to be safe. The Epione® robot could enhance the minimally invasive management of small and hard-to-reach lung tumors,” stated Professor Thierry De Baère, Interventional Radiologist in the Department of Therapeutic Imaging at Gustave Roussy and member of the scientific advisory board of Quantum Surgical.
Laetitia Messner, Chief Clinical Officer of Quantum Surgical, explains, “Coordinated by Professor De Baère, the clinical study has demonstrated the clinical performance and safety of Epione® in the treatment of lung tumors. The CE mark approval proves the relevance and effectiveness of Epione®, which will enable us to offer innovative, targeted, and less invasive treatments to new patients.”
Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera. This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or their location.
Relying on the know-how of the practitioner, Epione® integrates all the steps of a percutaneous ablation procedure in a single platform: planning, targeting, ablation, confirmation.
A demonstration video of the Epione® robot is available here.
Quantum Surgical will be present at the CIRSE conference in Copenhagen from September 9th to 13th.
The clinical study results will be presented by Dr. Baptiste Bonnet from Gustave Roussy on September 10th from 1 pm to 2 pm.
About Quantum Surgical
Quantum Surgical is a French medical robotics company based in Montpellier. As a key player in health innovation, Quantum Surgical develops concrete solutions to the major public health problem which is cancer. Available in Europe and the United States, its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. More than 200 patients have already been treated worldwide.
Co-founded in 2017 and with a team of 100+ employees, Quantum Surgical is based in Montpellier, with an international reach. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research.
More information: www.quantumsurgical.com
Press contact Quantum Surgical
Tel. : +33 (0)6 32 55 85 48